Disease Duration Among Patients Recruited to Alopecia Areata Clinical Trials: A Systematic Review

Abstract

Keywords

alopecia areata disease duration early intervention biologics clinical trials phase II phase III

Get full access to this article

View all access options for this article.

References

Rudnicka

Arenbergerova

Grimalt

, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687-694. doi:10.1111/jdv.19768

Sibbald

Alopecia areata: an updated review for 2023. J Cutan Med Surg. 2023;27(3):241-259. doi:10.1177/12034754231168839

Wada-Irimada

Takahashi

Sekine

, et al. Predictive factors for treatment responses to baricitinib in severe alopecia areata: a retrospective, multivariate analysis of 70 cases from a single center. J Dermatol. 2025;52(4):701-711. doi:10.1111/1346-8138.17641

Numata

Irisawa

Mori

Uchiyama

Harada

Baricitinib therapy for moderate to severe alopecia areata: a retrospective review of 95 Japanese patients. Acta Derm Venereol. 2024;104:adv18348. doi:10.2340/actadv.v104.18348

King

Mirmirani

Lo Sicco

, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025;39(6):1163-1173. doi:10.1111/jdv.20547

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

3.68 MB